Global Long-Acting Injectable Antipsychotics Market was valued at USD XX Billion in the year 2021. Global Long-Acting Injectable Antipsychotics Market is further estimated to grow at a CAGR of XX% from 2022 to 2030 it will reach USD XX Billion by the year 2030. The North America region holds the highest market share in 2021 and the Asia Pacific is considered as the fastest growing market in the forecasted period. At a country level, US, China are projected to grow strongly in the coming years due to increasing density of population and funding through Research and Development.
The Global Long-Acting Injectable Antipsychotics Report 2022-2030 covers market opportunities and challenges, key market regulations’ information, analysis of new products from the market players and key market trends, market share analysis for key players, supply chain and value chain analysis, product and Material trends, pricing analysis, emerging applications, technologies and major recent developments. This information has also been provided for the major country markets in these regions. Market shares, size and growth potential are assessed for these major country markets. Market opportunities, challenges, government regulations, market share analysis by major competitors, recent major market developments (product launches, M&A, partnerships, etc.) and other information have been covered for the major country markets listed in this section.
On the basis of Type, the market is divided as First-Generation and Second-Generation. In which First-Generation for the largest market share due to increasing demand in future market trends. Regional breakdown and deep analysis of each of the aforesaid segments is included for North America, Europe, Asia-Pacific, and ROW.
Market player analysis of major companies such as Johnson & Johnson, Eli Lily and Company, Alkermes Public Limited Company and Lundbeck...

1 INTRODUCTION
1.1 OBJECTIVES
1.2 RESEARCH METHODOLOGY
1.2.1 SECONDARY DATA
1.2.2 PRIMARY DATA
1.2.3 MARKET SIZE ESTIMATION
1.2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
1.3 STAKEHOLDERS
1.4 RESEARCH ASSUMPTIONS
1.5 LIMITATION
2 EXECUTIVE SUMMARY
3 MARKET OUTLOOK
3.1 INTRODUCTION
3.2 OPPORTUNITIES MATRIX
3.3 MARKET CHALLENGES
3.4 MARKET SHARE ANALYSIS
3.5 VALUE CHAIN ANALYSIS
3.6 DEMAND SIDE ANALYSIS
3.7 SUPPLY SIDE ANALYSIS
3.8 PORTER’S FIVE FORCES MODEL
3.8.1 DEGREE OF COMPETITION
3.8.2 BARGAINING POWER OF BUYERS
3.8.3 BARGAINING POWER OF SUPPLIERS
3.8.4 THREAT FROM SUBSTITUTES
3.8.5 THREAT FROM NEW ENTRANTS
4 INDUSTRY TRENDS
4.1 PRODUCT LIFE CYCLE
4.2 NEW MARKET ENTRY STRATEGY
4.3 PESTEL ANALYSIS
4.4 PRICING ANALYSIS
4.5 TRADE DATA
4.6 TECHNOLOGICAL OVERVIEW
4.7 FUTURE OUTLOOK MARKET TRENDS
4.8 MACRO-ECONOMIC VARIABLES (DEPENDENT AND INDEPENDENT VARIABLES)
4.9 MULTIFACTOR BASED SENSITIVITY ANALYSIS
4.10 REGRESSION MATRIX
4.11 COVID-19 IMPACT ANALYSES
4.12 GE MATRIX
5 LONG-ACTING INJECTABLE ANTIPSYCHOTICS TYPE ANALYSIS
5.1 INTRODUCTION
5.2 HISTORICAL MARKET TYPE ANALYSIS, 2016-2020
5.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030
5.4 Y-O-Y GROWTH TREND ANALYSIS
5.5 FIRST-GENERATION
5.6 SECOND-GENERATION
5.7 THIRD-GENERATION
6 LONG-ACTING INJECTABLE ANTIPSYCHOTICS DISTRIBUTION CHANNEL ANALYSIS
6.1 INTRODUCTION
6.2 HISTORICAL MARKET DISTRIBUTION CHANNEL ANALYSIS, 2016-2020
6.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030
6.4 Y-O-Y GROWTH TREND ANALYSIS
6.5 HOSPITAL PHARMACIES
6.6 RETAIL PHARMACIES
6.7 ONLINE PHARMACIES
7 LONG-ACTING INJECTABLE ANTIPSYCHOTICS MARKET APPLICATION ANALYSIS
7.1 INTRODUCTION
7.2 HISTORICAL MARKET APPLICATION ANALYSIS, 2016-2020
7.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030
7.4 Y-O-Y GROWTH TREND ANALYSIS
7.5 SCHIZOPHRENIA
7.6 DEMENTIA
7.7 BIPOLAR DISORDER
7.8 DEPRESSION
7.9 OTHERS
8 GLOBAL LONG-ACTING INJECTABLE ANTIPSYCHOTICS REGIONAL ANALYSIS
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2016-2020
8.2.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030
8.2.3 Y-O-Y GROWTH TREND ANALYSIS
8.2.3.1 U.S.
8.2.3.2 Canada
8.2.3.3 Mexico
8.3 ASIA-PACIFIC
8.3.1 APAC HISTORICAL MARKET COUNTRY ANALYSIS, 2016-2020
8.3.2 Y-O-Y GROWTH TREND ANALYSIS
8.3.2.1 China
8.3.2.2 Japan
8.3.2.3 Korea
8.3.2.4 India
8.3.2.5 Southeast Asia
8.4 MIDDLE EAST AND AFRICA
8.4.1 MIDDLE EAST AND AFRICA HISTORICAL MARKET COUNTRY ANALYSIS, 2016-2020
8.4.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030
8.4.3 Y-O-Y GROWTH TREND ANALYSIS
8.4.3.1 Saudi Arabia
8.4.3.2 UAE
8.4.3.3 Egypt
8.4.3.4 Nigeria
8.4.3.5 South Africa
8.5 EUROPE
8.5.1 EUROPE HISTORICAL MARKET COUNTRY ANALYSIS, 2016-2020
8.5.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030
8.5.3 Y-O-Y GROWTH TREND ANALYSIS
8.5.3.1 Germany
8.5.3.2 France
8.5.3.3 UK
8.5.3.4 Russia
8.5.3.5 Italy
8.6 LATIN AMERICA
8.6.1 LATIN AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2016-2020
8.6.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2021–2030
8.6.3 Y-O-Y GROWTH TREND ANALYSIS
8.6.3.1 Brazil
8.6.3.2 Argentina
8.6.3.3 Columbia
9 MARKET PLAYERS
9.1 JOHNSON & JOHNSON
9.1.1 BUSINESS OVERVIEW:
9.1.2 PRODUCT PORTFOLIO
9.1.3 RECENT DEVELOPMENTS
9.1.4 SWOT ANALYSIS:
9.2 ELI LILY AND COMPANY
9.3 ALKEREMES PUBLIC LIMITED COMPANY
9.4 LUNDBECK
9.5 ASTRAZENECA PLC
9.6 GLAXOSMITHKLINE PLC
9.7 OTSUKA PHARMACEUTICAL CO, LTD.
9.8 PFIZER INC.
9.9 ABBVIE INC.
9.10 BRISTOL-MYERS SQUIBB
9.11 TEVA PHARMACEUTICALS
9.12 DR. REDDY'S LABORATORIES
10 ABOUT US

TABLE 1 LONG-ACTING INJECTABLE ANTIPSYCHOTICS REGIONAL ANALYSIS, 2021–2030 (USD MILLION)
TABLE 2 GLOBAL LONG-ACTING INJECTABLE ANTIPSYCHOTICS MARKET, 2021–2030, (USD MILLION)
TABLE 3 LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE REGIONAL ANALYSIS, 2021–2030 (USD MILLION)
TABLE 4 GLOBAL LONG-ACTING INJECTABLE ANTIPSYCHOTICS HISTORICAL MARKET TYPE ANALYSIS, 2016-2020, (USD MILLION)
TABLE 5 LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 6 GLOBAL LONG-ACTING INJECTABLE ANTIPSYCHOTICS HISTORICAL MARKET DISTRIBUTION CHANNEL ANALYSIS, 2016-2020, (USD MILLION)
TABLE 7 LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE DISTRIBUTION CHANNEL ANALYSIS, 2021–2030 (USD MILLION)
TABLE 8 GLOBAL LONG-ACTING INJECTABLE ANTIPSYCHOTICS HISTORICAL MARKET APPLICATION ANALYSIS, 2016-2020, (USD MILLION)
TABLE 9 LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION)
TABLE 10 NORTH AMERICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS HISTORICAL MARKET ANALYSIS, 2016-2020, (USD MILLION)
TABLE 11 NORTH AMERICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 12 NORTH AMERICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE DISTRIBUTION CHANNEL ANALYSIS, 2021–2030 (USD MILLION)
TABLE 13 NORTH AMERICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION)
TABLE 14 U.S. LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2016–2021
TABLE 15 U.S. LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 16 U.S. LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 17 CANADA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 18 CANADA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 19 MEXICO LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 20 MEXICO LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 21 APAC LONG-ACTING INJECTABLE ANTIPSYCHOTICS HISTORICAL MARKET ANALYSIS, 2016-2020, (USD MILLION)
TABLE 22 ASIA-PACIFIC LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 23 ASIA-PACIFIC LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE DISTRIBUTION CHANNEL ANALYSIS, 2021–2030 (USD MILLION)
TABLE 24 ASIA-PACIFIC LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION)
TABLE 25 CHINA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 26 CHINA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 27 JAPAN LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 28 JAPAN LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 29 KOREA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 30 KOREA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 31 INDIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 32 INDIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 33 SOUTHEAST ASIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 34 SOUTHEAST ASIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS HISTORICAL MARKET ANALYSIS, 2016-2020, (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE DISTRIBUTION CHANNEL ANALYSIS, 2021–2030 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION)
TABLE 39 SAUDI ARABIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 40 SAUDI ARABIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 41 UAE LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 42 UAE LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 43 EGYPT LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 44 EGYPT LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 45 NIGERIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 46 NIGERIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 47 SOUTH AFRICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 48 SOUTH AFRICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 49 EUROPE LONG-ACTING INJECTABLE ANTIPSYCHOTICS HISTORICAL MARKET ANALYSIS, 2016-2020, (USD MILLION)
TABLE 50 EUROPE LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 51 EUROPE LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE DISTRIBUTION CHANNEL ANALYSIS, 2021–2030 (USD MILLION)
TABLE 52 EUROPE LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION)
TABLE 53 GERMANY LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 54 GERMANY LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 55 FRANCE LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 56 FRANCE LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 57 UK LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 58 UK LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 59 RUSSIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 60 RUSSIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 61 ITALY LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 62 ITALY LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 63 LATIN AMERICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS HISTORICAL MARKET ANALYSIS, 2016-2020, (USD MILLION)
TABLE 64 LATIN AMERICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030 (USD MILLION)
TABLE 65 LATIN AMERICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE DISTRIBUTION CHANNEL ANALYSIS, 2021–2030 (USD MILLION)
TABLE 66 LATIN AMERICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030 (USD MILLION)
TABLE 67 BRAZIL LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 68 BRAZIL LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 69 ARGENTINA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 70 ARGENTINA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
TABLE 71 COLUMBIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
TABLE 72 COLUMBIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 1 GLOBAL LONG-ACTING INJECTABLE ANTIPSYCHOTICS MARKET, 2021–2030, (USD MILLION)
FIGURE 2 RESEARCH METHODOLOGY
FIGURE 3 GLOBAL LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE MARKET, 2021–2030, (USD MILLION)
FIGURE 4 GLOBAL LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE MARKET, 2021–2030, (USD MILLION)
FIGURE 5 MARKET OVERVIEW
FIGURE 6 SWOT ANALYSIS
FIGURE 7 MARKET SHARE ANALYSIS
FIGURE 8 SUPPLY CHAIN ANALYSIS
FIGURE 9 PORTER’S FIVE FORCES ANALYSIS
FIGURE 10 LONG-ACTING INJECTABLE ANTIPSYCHOTICS TYPE ANALYSIS
FIGURE 11 GLOBAL LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE MARKET TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 12 LONG-ACTING INJECTABLE ANTIPSYCHOTICS DISTRIBUTION CHANNEL ANALYSIS
FIGURE 13 GLOBAL LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE MARKET DISTRIBUTION CHANNEL ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 14 LONG-ACTING INJECTABLE ANTIPSYCHOTICS APPLICATION ANALYSIS
FIGURE 15 GLOBAL LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE MARKET APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 16 GLOBAL LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE MARKET VOLUME SHARE REGIONAL ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 17 MARKET OVERVIEW, REGIONAL ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 18 MARKET SHARE BY COUNTRY
FIGURE 19 NORTH AMERICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 20 NORTH AMERICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE DISTRIBUTION CHANNEL ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 21 NORTH AMERICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 22 U.S. LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 23 U.S. LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 24 CANADA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 25 CANADA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 26 MEXICO LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 27 MEXICO LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 28 MARKET SHARE BY COUNTRY
FIGURE 29 APAC LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 30 APAC LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE DISTRIBUTION CHANNEL ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 31 APAC LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 32 CHINA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 33 CHINA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 34 JAPAN LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 35 JAPAN LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 36 KOREA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 37 KOREA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 38 INDIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 39 INDIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 40 SOUTHEAST ASIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 41 SOUTHEAST ASIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 42 MARKET SHARE BY COUNTRY
FIGURE 43 MIDDLE EAST AND AFRICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 44 MIDDLE EAST AND AFRICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE DISTRIBUTION CHANNEL ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 45 MIDDLE EAST AND AFRICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 46 SAUDI ARABIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 47 SAUDI ARABIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 48 UAE LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 49 UAE LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 50 EGYPT LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 51 EGYPT LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 52 NIGERIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 53 NIGERIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 54 SOUTH AFRICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 55 SOUTH AFRICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 56 MARKET SHARE BY COUNTRY
FIGURE 57 EUROPE LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 58 EUROPE LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE DISTRIBUTION CHANNEL ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 59 EUROPE LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 60 GERMANY LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 61 GERMANY LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 62 FRANCE LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 63 FRANCE LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 64 UK LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 65 UK LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 66 RUSSIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 67 RUSSIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 68 ITALY LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 69 ITALY LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 70 MARKET SHARE BY COUNTRY
FIGURE 71 LATIN AMERICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 72 LATIN AMERICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE DISTRIBUTION CHANNEL ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 73 LATIN AMERICA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 74 BRAZIL LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 75 BRAZIL LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 76 ARGENTINA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 77 ARGENTINA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 78 COLUMBIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE TYPE ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 79 COLUMBIA LONG-ACTING INJECTABLE ANTIPSYCHOTICS CURRENT AND FUTURE APPLICATION ANALYSIS, 2021–2030, (USD MILLION)
FIGURE 80 FINANCIAL OVERVIEW: